Pluristem Announces One-for-Ten Reverse Split of its Common Shares
24 juil. 2019 02h45 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, July 24, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Pluristem and U.S. Department of Defense to Announce Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome at RITN
17 juil. 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
Data will be jointly presented at the upcoming 2019 Radiation Injury Treatment Network (RITN) Workshop on July 31st HAIFA, Israel, July 17, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc....
Pluristem Therapeutics’ CEO Issues Shareholder Letter
02 juil. 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, July 02, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Pluristem Completes Transition Period of Co-CEO Structure Yaky Yanay appointed as Chief Executive Officer and Zami Aberman appointed as Executive Chairman of the Board
24 juin 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, June 24, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Pluristem Strengthens Its Manufacturing Competitive Advantage, Presents its First Proprietary Serum-Free Cell Therapy Product
17 juin 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, June 17, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Lead Physicians in Pluristem’s Pivotal Study in Critical Limb Ischemia Publish Peer-Reviewed Paper
15 mai 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, May 15, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Pluristem Files Patent Application for the Use of its Advanced Manufacturing Technology in the Cannabis Industry
06 mai 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, May 06, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
Pluristem Completes Interim Enrollment in Pivotal CLI Study, Targeting Potential Conditional Marketing Approval in Europe
29 avr. 2019 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, April 29, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy...
Pluristem Therapeutics Issues Shareholder Update
23 avr. 2019 08h00 HE
|
Pluristem Therapeutics, Inc.
Recent financing provides funding through multiple potentially value-creating milestonesProviding short and mid-term milestones, targeting marketing and significant contracts HAIFA, Israel, April ...
Pluristem Therapeutics Inc. Announces Pricing of Its Public Offering and Registered Direct Offering for Aggregate Proceeds of Approximately $20 Million
04 avr. 2019 09h17 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Isreal, April 04, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PLTR) (“Pluristem” or “Company”), a leading regenerative medicine company developing novel...